Galmed Pharmaceuticals Aramchol Phase 3 NASH 2021

Galmed Pharmaceuticals presents Aramchol, a first-in-class SCD-1 modulator in Phase 3 development for NASH (non-alcoholic steatohepatitis). The presentation outlines the ARMOR trial expected to reach last patient enrollment in Q4 2021, clinical trial data across 500+ subjects, and FDA Fast Track designation status.